基于解毒通络法探讨内外合治糖尿病足的临床疗效研究

注册号:

Registration number:

ITMCTR2100004549

最近更新日期:

Date of Last Refreshed on:

2020-12-01

注册时间:

Date of Registration:

2020-12-01

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于解毒通络法探讨内外合治糖尿病足的临床疗效研究

Public title:

The clinical efficacy study-based on the method of detoxification and collateralization for internal and external treatment of diabetic foot

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于解毒通络法探讨内外合治糖尿病足的临床疗效研究

Scientific title:

The clinical efficacy study-based on the method of detoxification and collateralization for internal and external treatment of diabetic foot

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000040538 ; ChiMCTR2100004549

申请注册联系人:

贾慧

研究负责人:

贾慧

Applicant:

Hui Jia

Study leader:

Hui Jia

申请注册联系人电话:

Applicant telephone:

+86 18701617505

研究负责人电话:

Study leader's telephone:

+86 18701617505

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

drjiahui@sina.com

研究负责人电子邮件:

Study leader's E-mail:

drjiahui@sina.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市顺义区站前东街5号

研究负责人通讯地址:

北京市顺义区站前东街5号

Applicant address:

5 Zhanqian Street East, Shunyi District, Beijing, China

Study leader's address:

5 Zhanqian Street East, Shunyi District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医医院顺义医院

Applicant's institution:

Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020SYKY12-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

北京中医医院顺义医院医学伦理委员会

Name of the ethic committee:

Ethic committee of Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020/9/10 0:00:00

伦理委员会联系人:

郭华

Contact Name of the ethic committee:

Hua Guo

伦理委员会联系地址:

北京市顺义区站前东街5号

Contact Address of the ethic committee:

5 Zhanqian Street East, Shunyi District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医医院顺义医院

Primary sponsor:

Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital

研究实施负责(组长)单位地址:

北京市顺义区站前东街5号

Primary sponsor's address:

5 Zhanqian Street East, Shunyi District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医医院顺义医院

具体地址:

北京市顺义区站前东街5号

Institution
hospital:

Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital

Address:

5 Zhanqian Street East, Shunyi District, Beijing, China

经费或物资来源:

北京市医院管理中心

Source(s) of funding:

BEIJING HOSPITALS AUTHORITY

研究疾病:

糖尿病足

研究疾病代码:

Target disease:

Diabetic foot

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

应用解毒通络法干预糖尿病足瘀毒阻络证患者,通过观察基线特征、中医症候评价、创面疗效评价、生活质量评价、安全性评价,阐明解毒通络法治疗糖尿病足的科学内涵并扩展其应用。

Objectives of Study:

By observing the baseline characteristics, TCM syndrome evaluation, wound efficacy evaluation, quality of life evaluation, and safety evaluation, the scientific connotation and application of detoxification and collateralization method in the treatment of diabetic foot were clarified.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合糖尿病病足诊断标准,中医辨证符合瘀毒阻络证,符合Wagner分级在0~Ⅲ级。 ②年龄在40~90岁之间。 ③签署知情同意书,自愿参加本研究,依从性好,可随访者。

Inclusion criteria

①In accordance with diabetic foot disease diagnostic criteria, syndrome differentiation of traditional Chinese medicine conforms to the stasis poison resistance network, in accordance with Wagner class in 0-Ⅲ. ②Between 40 and 90 years old. ③Sign informed consent form and participate in this study voluntarily. Compliance is good.

排除标准:

①入院时为局部坏死严重,需进行截肢术者; ②合并肿瘤、遗传性、传染性疾病等其他严重疾病或预期生存期较短的患者; ③有明显心、肝、肾功能不全者;重度营养不良者及其他全身感染情况; ④合并精神疾病者; ⑤孕妇或准备怀孕的妇女; ⑥酗酒或吸毒者; ⑦过敏体质者; ⑧同时或随机入组前4周内参加其他试验患者。

Exclusion criteria:

①Severe local necrosis at the time of admission, requiring amputation; ②Patients with other serious diseases such as tumor, genetic disease, infectious disease or with a short expected survival time; ③Patients with obvious cardiac, hepatic and renal insufficiency; Severe malnutrition and other systemic infections; ④persons with mental illness; ⑤Pregnant women or women who are preparing to become pregnant; ⑥Alcoholism or drug addiction; ⑦Allergic constitution; ⑧Patients were enrolled in other trials at the same time or within 4 weeks prior to randomization.

研究实施时间:

Study execute time:

From 2020-07-01

To      2023-06-30

征募观察对象时间:

Recruiting time:

From 2020-12-01

To      2023-06-30

干预措施:

Interventions:

组别:

对照组

样本量:

45

Group:

The control group

Sample size:

干预措施:

常规内外科基础治疗+外用溃疡油

干预措施代码:

Intervention:

Conventional basic internal and surgical treatment + external ulcer oil

Intervention code:

组别:

试验组

样本量:

45

Group:

The experimental group

Sample size:

干预措施:

常规内外科基础治疗+外用溃疡油+解毒通脉颗粒

干预措施代码:

Intervention:

Conventional basic internal and surgical treatment + external ulcer oil +Jiedu Tongmai granule

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医医院顺义医院

单位级别:

三级甲等

Institution/hospital:

Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

下肢血管超声评价

指标类型:

次要指标

Outcome:

Lower extremity vascular ultrasound evaluation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医症候评价

指标类型:

次要指标

Outcome:

Evaluation of TCM syndromes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评分SF-36量表

指标类型:

主要指标

Outcome:

short form 36 questionnaire

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床检验指标

指标类型:

副作用指标

Outcome:

Clinical indicators

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 40
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者应用SPSS20.0统计软件进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomization was designed with SPSS20.0 by researchers.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

待定

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统